East Hanover, June 16, 2020 – Novartis drug Ilaris (canakinumab) received US Food and Drug Administration (FDA) approval for a new indication to treat Adult-Onset Still’s Disease (AOSD)1. The FDA granted an indication for active Still’s…Original Article
Ilaris (canakinumab) Receives FDA Approval for New Indication to Treat Adult-Onset Still’s Disease (AOSD)
